Intestinal organoids: A model of intestinal fibrosis for evaluating anti-fibrotic drugs

Experimental and Molecular Pathology

Volumn 98, Issue 3, 2015, Pages 346-351

  Rodansky, Eva S ^a   Johnson, Laura A ^a   Huang, Sha ^a   Spence, Jason R ^a   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Drug screening; Fibrosis model; Myofibroblasts; Organoid; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; DESMIN; MYOSIN LIGHT CHAIN KINASE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; ACTA2 PROTEIN, HUMAN; ACTIN; CALCIUM BINDING PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; FIBRONECTIN; FN1 PROTEIN, HUMAN; MKL1 PROTEIN, HUMAN; MYLK PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ACTA2 GENE; ARTICLE; CELL STIMULATION; COL1A1 GENE; CONTROLLED STUDY; CYTOPLASM; DRUG MECHANISM; DRUG SCREENING; EMBRYO; ENZYME ACTIVATION; FIBROGENESIS; FN1 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL FIBROSIS; INTESTINAL ORGANOID; MESENCHYME; MKL1 GENE; MYLK GENE; MYOFIBROBLAST; PLURIPOTENT STEM CELL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; EMBRYONIC STEM CELL; FIBROSIS; GENETICS; INTESTINE; METABOLISM; PATHOLOGY;

RODENTIA;

ACTINS; CALCIUM-BINDING PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE I; EMBRYONIC STEM CELLS; FIBRONECTINS; FIBROSIS; HUMANS; INTESTINES; MYOFIBROBLASTS; MYOSIN-LIGHT-CHAIN KINASE; ORGANOIDS; PLURIPOTENT STEM CELLS; SPIRONOLACTONE; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84926367272     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.03.033     Document Type: Article

References (34)

1. Andres P.G., Friedman L.S. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol. Clin. N. Am. 1999, 28:255-281. (vii).
2. Astashkina A., Grainger D.W. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv. Drug Deliv. Rev. 2014, 69-70:1-18.
3. Brenna O., et al. Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and transcriptomic [corrected] characterization and correlation to IBD. PLoS One 2013, 8:e54543.
4. Chen X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
5. Chen Y.J., et al. De novo formation of insulin-producing "neo-beta cell islets" from intestinal crypts. Cell Rep. 2014, 6:1046-1058.
6. Collard H.R., et al. Burden of illness in idiopathic pulmonary fibrosis. J. Med. Econ. 2012, 15:829-835.
7. Collins A.J., et al. Excerpts from the US Renal Data System 2009 annual data report. Am. J. Kidney Dis. 2010, 55(S1-420):A6-A7.
8. Ersoy R., et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit. Dial. Int. 2007, 27:424-431.
9. Grassl G.A., et al. Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology 2008, 134:768-780.
10. Gullulu M., et al. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren. Fail. 2006, 28:509-514.
11. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J. Biomech. 2010, 43:146-155.
12. Horowitz J.C., et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int. J. Biochem. Cell Biol. 2012, 44:158-169.
13. Johnson L.A., et al. Spironolactone and colitis: increased mortality in rodents and in humans. Inflamm. Bowel Dis. 2012, 18:1315-1324.
14. Johnson L.A., et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in mice. Inflamm. Bowel Dis. 2012, 18:460-471.
15. Johnson L.A., et al. CARD-024, a vitamin D analog, attenuates the pro-fibrotic response to substrate stiffness in colonic myofibroblasts. Exp. Mol. Pathol. 2012, 93:91-98.
16. Johnson L.A., et al. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts. Inflamm. Bowel Dis. 2013, 19:891-903.
17. Johnson L.A., et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm. Bowel Dis. 2014, 20:154-165.
18. Kim K., et al. Noninvasive ultrasound elasticity imaging (UEI) of Crohn's disease: animal model. Ultrasound Med. Biol. 2008, 34:902-912.
19. Leslie J.L., et al. Persistence and toxin production by Clostridium difficile within human intestinal organoids results in disruption of epithelial paracellular barrier function. Infect. Immun. 2014, 83:138-145.
20. Liu F., et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J. Cell Biol. 2010, 190:693-706.
21. McCracken K.W., et al. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat. Protoc. 2011, 6:1920-1928.
22. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
23. Mih J.D., et al. A multiwell platform for studying stiffness-dependent cell biology. PLoS One 2011, 6:e19929.
24. Neff G.W., et al. The current economic burden of cirrhosis. Gastroenterol. Hepatol. 2011, 7:661-671.
25. Neurath M., et al. TNBS-colitis. Int. Rev. Immunol. 2000, 19:51-62.
26. Nishimura H., et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am. J. Physiol. Ren. Physiol. 2008, 294:F1084-F1093.
27. O'Connell J.B., Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transplant. 1994, 13:S107-S112.
28. Pitt B., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
29. Powell D.W., et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am. J. Physiol. 1999, 277:C183-C201.
30. Rajagopalan S., Pitt B. Aldosterone as a target in congestive heart failure. Med. Clin. North Am. 2003, 87:441-457.
31. Ranga A., et al. Drug discovery through stem cell-based organoid models. Adv. Drug Deliv. Rev. 2014, 69-70:19-28.
32. Rieder F., et al. Wound healing and fibrosis in intestinal disease. Gut 2007, 56:130-139.
33. Sands B.E., et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am. J. Gastroenterol. 2003, 98:2712-2718.
34. Spence J.R., et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 2011, 470:105-109.